Skip to content
Peptigraph home

CJC-1295 vs IGF-1 LR3: What the Research Shows

CJC-1295 and IGF-1 LR3 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[4]Growth hormoneIGF-1 analogNot FDA approved · research chemicalIGF-1 LR3IGF-1 LR3, a long-acting IGF-1 analog with no published human trial; in rats it was 2.5 to 3 times more potent than IGF-I at restoring growth.[15]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider CJC-1295 if…

  • you want randomized human hormone data (hormone levels, not a clinical benefit): a single injection raised mean plasma GH 2- to 10-fold for 6 days or more[4]

Consider IGF-1 LR3 if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

  • Only animal or lab studies of IGF-1 LR3 were found (e.g. rat): The IGF-I variants were 2.5-3 times more potent than IGF-I at restoring growth in diabetic rats.[15]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 9 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026 are the same or both unknown.

FieldCJC-1295IGF-1 LR3
ClassGHRH analogIGF-1 analog
Also calledCJC, mod GRF, GRF 1-29LR3
WADAProhibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302
Evidence strengthHuman RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised1 human (0 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg0.1 mg, 1 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Upstream signal versus downstream hormone

CJC-1295 is a GHRH analogue, which acts upstream of GH, while IGF-1 LR3 is an analogue of IGF-1 itself. A recent review lists them in separate groups of agents seen in online self-administration protocols.[17]

Human data exist for CJC-1295 but none are cited for IGF-1 LR3. In the main CJC-1295 trial, GH and IGF-I levels rose dose-dependently in healthy adults.[4]

The only human-related paper cited on IGF-1 LR3 analyses a black-market vial. It says the effects of His-tagged Long-R3-IGF-I in humans have not been elucidated.[10]

What the IGF-1 LR3 animal studies show, and how mixed they are

In streptozotocin-induced diabetic rats, two IGF-I variants including LR3-IGF-I were 2.5-3 times more potent than IGF-I at restoring growth.[15]

In pigs, an infusion of Long R3 IGF-I decreased average daily gain and food intake.[18]

In growth-restricted fetal sheep, a 1-week IGF-1 LR3 treatment did not improve growth.[11]

In a rat wound chamber, LR3-IGF-I was cleared from wound fluid faster than IGF-I, with a half-life of 563 min.[9]

Common questions

CJC-1295 vs IGF-1 LR3: which is better for muscle?

Neither has a human trial for muscle. CJC-1295's trial measured GH and IGF-I levels in healthy adults, and the IGF-1 LR3 papers cited are animal studies and a product analysis.[4]

Is IGF-1 LR3 safe?

Its effects in humans have not been described in the papers cited. Animal results are mixed, including reduced growth gain in pigs.[18]

Do CJC-1295 and IGF-1 LR3 do the same thing?

No. CJC-1295 is a GHRH analogue, and IGF-1 LR3 is an analogue of IGF-1.[17]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  5. 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  6. 6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  7. 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
  10. 10Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
  11. 11IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
  12. 12Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
  13. 13Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
  14. 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab])))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
  16. 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  18. 18Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026

Found an error? Report a correction.